View Tagrisso overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Take at the same time each day. Swallow whole, do not crush/split/chew. For patients w/ swallowing difficulties, tab may be dispersed in 50 mL non-carbonated water & stir w/o crushing until dispersed. Drink immediately. Rinse glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via nasogastric tube by using 15 mL for initial dispersion & 15 mL for residue rinses. The tube should be flushed w/ water after administration. Administer soln w/in 30 min after prep.
Contraindications
Hypersensitivity. Not to be used w/ St. John's wort.
Discontinue use if ILD is diagnosed, signs & symptoms of SJS appears, QTc interval prolongation in combination w/ Torsade de pointes, polymorphic ventricular tachycardia, signs/symptoms of serious arrhythmia develops & aplastic anaemia is confirmed. Avoid use in patients w/ congenital long QT syndrome. Keratitis. Determine EGFR mutation +ve status prior to treatment. Periodically monitor ECG & electrolytes in patients w/ CHF, electrolyte abnormalities or those taking QTc prolonging medicinal products. Perform cardiac monitoring & LVEF assessment in patients w/ cardiac risk factors & conditions affecting LVEF. Low body wt <50 kg. Not recommended in severe hepatic impairment. Severe renal impairment, ESRD. May impair fertility. Women of childbearing potential must use effective contraception at least 2 mth & at least 4 mth for men after treatment completion. Not to be used during pregnancy & lactation. Childn or adolescents <18 yr. Elderly >65 yr.
Sign Out
